Pulmonx (NASDAQ:LUNG – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Profitability
This table compares Pulmonx and Azenta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -60.09% | -92.94% | -39.80% |
| Azenta | -30.49% | 1.23% | 1.02% |
Insider and Institutional Ownership
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 10.9% of Azenta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 2 | 4 | 0 | 2.43 |
| Azenta | 1 | 3 | 4 | 0 | 2.38 |
Pulmonx currently has a consensus price target of $5.58, suggesting a potential upside of 294.58%. Azenta has a consensus price target of $39.50, suggesting a potential upside of 49.89%. Given Pulmonx’s stronger consensus rating and higher probable upside, research analysts plainly believe Pulmonx is more favorable than Azenta.
Earnings & Valuation
This table compares Pulmonx and Azenta”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 0.66 | -$54.00 million | ($1.30) | -1.09 |
| Azenta | $593.82 million | 2.05 | -$55.76 million | ($3.96) | -6.65 |
Pulmonx has higher earnings, but lower revenue than Azenta. Azenta is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Pulmonx has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
Summary
Azenta beats Pulmonx on 8 of the 13 factors compared between the two stocks.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
